SG11201707429VA - Novel therapies for cancer - Google Patents
Novel therapies for cancerInfo
- Publication number
- SG11201707429VA SG11201707429VA SG11201707429VA SG11201707429VA SG11201707429VA SG 11201707429V A SG11201707429V A SG 11201707429VA SG 11201707429V A SG11201707429V A SG 11201707429VA SG 11201707429V A SG11201707429V A SG 11201707429VA SG 11201707429V A SG11201707429V A SG 11201707429VA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- novel therapies
- therapies
- novel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562141980P | 2015-04-02 | 2015-04-02 | |
| PCT/IB2016/051880 WO2016157149A1 (en) | 2015-04-02 | 2016-04-01 | Novel therapies for cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201707429VA true SG11201707429VA (en) | 2017-10-30 |
Family
ID=55702039
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201707429VA SG11201707429VA (en) | 2015-04-02 | 2016-04-01 | Novel therapies for cancer |
| SG10201909188X SG10201909188XA (en) | 2015-04-02 | 2016-04-01 | Novel therapies for cancer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201909188X SG10201909188XA (en) | 2015-04-02 | 2016-04-01 | Novel therapies for cancer |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11311552B2 (en) |
| EP (1) | EP3277284B1 (en) |
| JP (1) | JP6927882B2 (en) |
| KR (1) | KR20170132314A (en) |
| CN (2) | CN107438437B (en) |
| AU (1) | AU2016242118B2 (en) |
| BR (1) | BR112017019437A2 (en) |
| CA (1) | CA2979167A1 (en) |
| DK (1) | DK3277284T3 (en) |
| EA (1) | EA037555B1 (en) |
| ES (1) | ES2826558T3 (en) |
| HK (1) | HK1245120A1 (en) |
| HU (1) | HUE051341T2 (en) |
| IL (1) | IL254149A0 (en) |
| MX (1) | MX2017011981A (en) |
| PL (1) | PL3277284T3 (en) |
| PT (1) | PT3277284T (en) |
| SG (2) | SG11201707429VA (en) |
| WO (1) | WO2016157149A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201017345D0 (en) | 2010-10-14 | 2010-11-24 | Proximagen Ltd | Receptor antagonists |
| SG11201707429VA (en) | 2015-04-02 | 2017-10-30 | Proximagen Ltd | Novel therapies for cancer |
| GB201604213D0 (en) | 2016-03-11 | 2016-04-27 | Proximagen Ltd | Drug combination and its use in therapy |
| GB201703907D0 (en) * | 2017-03-10 | 2017-04-26 | Proximagen Ltd | Novel therapies for cancer |
| WO2020222189A1 (en) | 2019-05-02 | 2020-11-05 | Proximagen, Llc | Crystalline form of 6-[4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl]-n-(pyrdin-4-yl)pyridine-2-carboxamide |
| WO2020222190A1 (en) | 2019-05-02 | 2020-11-05 | Proximagen, Llc | Crystalline form of 6-[4-[1 -(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1 -yl]-n-(pyrdin-4-yl)pyridine-2-carboxamide |
| KR20230031285A (en) | 2020-06-26 | 2023-03-07 | 라퀄리아 파마 인코포레이티드 | Method for selecting cancer patients for which combination therapy of retinoid and cancer drug is effective and combination medicine of retinoid and cancer drug |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5047406A (en) | 1989-12-06 | 1991-09-10 | Warner-Lambert Co. | Substituted cyclohexanols as central nervous system agents |
| GB9300194D0 (en) | 1993-01-06 | 1993-03-03 | Wyeth John & Brother Ltd | Piperazine derivatives |
| US6506770B1 (en) | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
| US5939098A (en) * | 1996-09-19 | 1999-08-17 | Schering Corporation | Cancer treatment with temozolomide |
| AU5522498A (en) | 1996-12-13 | 1998-07-03 | Merck & Co., Inc. | Substituted aryl piperazines as modulators of chemokine receptor activity |
| FR2769913B1 (en) | 1997-10-16 | 2000-03-10 | Pf Medicament | NEW CYCLOHEXANIC DERIVATIVES DIFUNCTIONALIZED IN 1, 4, THEIR PREPARATION AND THEIR HUMAN THERAPEUTIC APPLICATION |
| SE9902987D0 (en) | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
| WO2002002539A1 (en) | 2000-06-29 | 2002-01-10 | Abbott Laboratories | Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
| AR036366A1 (en) | 2001-08-29 | 2004-09-01 | Schering Corp | USEFUL PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS, THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND A KIT |
| WO2003082855A1 (en) | 2002-03-28 | 2003-10-09 | Kyowa Hakko Kogyo Co., Ltd. | Anti-inflammatory agent |
| AU2003288994A1 (en) | 2002-12-10 | 2004-06-30 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic compounds and medicinal use thereof |
| EP1608318A4 (en) * | 2003-03-27 | 2009-07-29 | Univ Emory | Cxcr4 antagonists and methods of their use |
| GB0308466D0 (en) | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
| FR2854633B1 (en) | 2003-05-07 | 2005-06-24 | Sanofi Synthelabo | PIPERIDINYL-AND PIPERAZINYL-ALKYLCARBAMATES DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
| US7491735B2 (en) | 2003-12-11 | 2009-02-17 | Genzyme Corporation | Chemokine receptor binding compounds |
| US7498346B2 (en) | 2003-12-11 | 2009-03-03 | Genzyme Corporation | Chemokine receptor binding compounds |
| WO2006071958A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| WO2006071875A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| CN101213185A (en) | 2005-02-16 | 2008-07-02 | 先灵公司 | Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity |
| US7417045B2 (en) | 2005-02-16 | 2008-08-26 | Schering Corporation | Heterocyclic substituted pyridine or phenyl compounds with CXCR3 antagonist activity |
| US7566718B2 (en) | 2005-02-16 | 2009-07-28 | Schering Corporation | Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity |
| EP1856098B1 (en) | 2005-02-16 | 2012-08-01 | Schering Corporation | Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity |
| MX2007010068A (en) | 2005-02-16 | 2007-10-10 | Schering Corp | Piperazine-piperidines with cxcr3 antagonist activity. |
| US20060235028A1 (en) | 2005-04-14 | 2006-10-19 | Li James J | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I |
| WO2006130426A2 (en) | 2005-05-27 | 2006-12-07 | Kemia, Inc. | Modulators of ccr-5 activity |
| GB0525957D0 (en) | 2005-12-21 | 2006-02-01 | Astrazeneca Ab | Methods |
| JP2009530383A (en) | 2006-03-21 | 2009-08-27 | シェーリング コーポレイション | Novel heterocyclic pyridine-substituted product having CXCR3 antagonistic activity |
| EP1849781A1 (en) | 2006-04-28 | 2007-10-31 | Laboratorios del Dr. Esteve S.A. | Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments |
| MX2009000577A (en) | 2006-07-14 | 2009-03-09 | Schering Corp | Heterocyclic substituted piperazine compounds with cxcr3 antagonist activity. |
| WO2008028553A1 (en) | 2006-09-02 | 2008-03-13 | Merck Patent Gmbh | Particle beam process for the alignment of reactive mesogens |
| US7879846B2 (en) | 2006-09-21 | 2011-02-01 | Kyorin Pharmaceutical Co.., Ltd. | Serine hydrolase inhibitors |
| JP2010510224A (en) | 2006-11-17 | 2010-04-02 | アボット・ラボラトリーズ | Aminopyrrolidines as chemokine receptor antagonists |
| EP2094688A1 (en) | 2006-12-22 | 2009-09-02 | Schering Corporation | Heterocyclic compounds with cxcr3 antagonist activity |
| EP2121613A2 (en) | 2007-01-31 | 2009-11-25 | Vertex Pharmaceuticals, Inc. | 2-aminopyridine derivatives useful as kinase inhibitors |
| WO2008121065A1 (en) | 2007-03-30 | 2008-10-09 | Astrazeneca Ab | Novel pyrrolidine derivatives as antagonists of the chemokine receptor |
| WO2009071701A1 (en) | 2007-12-07 | 2009-06-11 | Novartis Ag | Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases |
| EP2262494A2 (en) * | 2008-02-29 | 2010-12-22 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of post-radiation tumor growth by an inhibitor of vasculogenesis |
| US8288373B2 (en) | 2008-11-04 | 2012-10-16 | Chemocentryx, Inc. | Modulators of CXCR7 |
| JP2012533553A (en) | 2009-07-15 | 2012-12-27 | アボット・ラボラトリーズ | Pyrrolopyridine kinase inhibitor |
| KR20110123657A (en) | 2010-05-07 | 2011-11-15 | 에스케이케미칼주식회사 | Picolinamide and pyrimidine-4-carboxamide compounds, process for preparing and pharmaceutical composition comprising the same |
| WO2012047339A2 (en) | 2010-06-28 | 2012-04-12 | The General Hospital Corporation | Anti-cxcr4 as a sensitizer to cancer therapeutics |
| GB201017048D0 (en) * | 2010-10-08 | 2010-11-24 | Ucl Business Plc | Composition |
| GB201017345D0 (en) | 2010-10-14 | 2010-11-24 | Proximagen Ltd | Receptor antagonists |
| AU2013362757B2 (en) * | 2012-12-20 | 2018-06-14 | Qing-bin LU | Radiosensitizer compounds for use in combination with radiation |
| SG11201707429VA (en) | 2015-04-02 | 2017-10-30 | Proximagen Ltd | Novel therapies for cancer |
| GB201604213D0 (en) | 2016-03-11 | 2016-04-27 | Proximagen Ltd | Drug combination and its use in therapy |
| GB201703907D0 (en) | 2017-03-10 | 2017-04-26 | Proximagen Ltd | Novel therapies for cancer |
-
2016
- 2016-04-01 SG SG11201707429VA patent/SG11201707429VA/en unknown
- 2016-04-01 AU AU2016242118A patent/AU2016242118B2/en not_active Expired - Fee Related
- 2016-04-01 BR BR112017019437A patent/BR112017019437A2/en not_active Application Discontinuation
- 2016-04-01 SG SG10201909188X patent/SG10201909188XA/en unknown
- 2016-04-01 WO PCT/IB2016/051880 patent/WO2016157149A1/en active Application Filing
- 2016-04-01 PL PL16715626T patent/PL3277284T3/en unknown
- 2016-04-01 CN CN201680020617.7A patent/CN107438437B/en not_active Expired - Fee Related
- 2016-04-01 DK DK16715626.4T patent/DK3277284T3/en active
- 2016-04-01 MX MX2017011981A patent/MX2017011981A/en unknown
- 2016-04-01 EA EA201791953A patent/EA037555B1/en unknown
- 2016-04-01 US US15/562,741 patent/US11311552B2/en active Active
- 2016-04-01 ES ES16715626T patent/ES2826558T3/en active Active
- 2016-04-01 CA CA2979167A patent/CA2979167A1/en not_active Abandoned
- 2016-04-01 JP JP2017548463A patent/JP6927882B2/en active Active
- 2016-04-01 CN CN202011468330.5A patent/CN112569242A/en active Pending
- 2016-04-01 HU HUE16715626A patent/HUE051341T2/en unknown
- 2016-04-01 KR KR1020177031648A patent/KR20170132314A/en not_active Application Discontinuation
- 2016-04-01 PT PT167156264T patent/PT3277284T/en unknown
- 2016-04-01 EP EP16715626.4A patent/EP3277284B1/en active Active
-
2017
- 2017-08-24 IL IL254149A patent/IL254149A0/en unknown
-
2018
- 2018-04-10 HK HK18104660.1A patent/HK1245120A1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HK1245120A1 (en) | 2018-08-24 |
| HUE051341T2 (en) | 2021-03-01 |
| CN107438437B (en) | 2021-01-01 |
| WO2016157149A9 (en) | 2016-12-08 |
| EP3277284A1 (en) | 2018-02-07 |
| US20180078563A1 (en) | 2018-03-22 |
| MX2017011981A (en) | 2018-01-10 |
| WO2016157149A1 (en) | 2016-10-06 |
| ES2826558T3 (en) | 2021-05-18 |
| CN112569242A (en) | 2021-03-30 |
| EA201791953A1 (en) | 2018-01-31 |
| PL3277284T3 (en) | 2021-03-08 |
| SG10201909188XA (en) | 2019-11-28 |
| AU2016242118A1 (en) | 2017-10-05 |
| JP6927882B2 (en) | 2021-09-01 |
| AU2016242118B2 (en) | 2021-07-08 |
| DK3277284T3 (en) | 2020-10-26 |
| CN107438437A (en) | 2017-12-05 |
| JP2018510154A (en) | 2018-04-12 |
| EP3277284B1 (en) | 2020-08-05 |
| KR20170132314A (en) | 2017-12-01 |
| EA037555B1 (en) | 2021-04-13 |
| US11311552B2 (en) | 2022-04-26 |
| BR112017019437A2 (en) | 2018-05-02 |
| IL254149A0 (en) | 2017-10-31 |
| CA2979167A1 (en) | 2016-10-06 |
| PT3277284T (en) | 2020-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201702382B (en) | Combination therapy for cancer | |
| IL254705B (en) | Combination therapy for cancer | |
| IL253573A0 (en) | Combination therapies for treating cancers | |
| HK1259342A1 (en) | Combination therapies for treating cancer | |
| HK1231381A1 (en) | Combination therapy for cancer | |
| HK1245120A1 (en) | Novel therapies for cancer | |
| HK1243598A1 (en) | Combination therapies | |
| IL246761A0 (en) | Combination therapy for cancer | |
| HK1255939A1 (en) | Combination therapies for treating cancers | |
| GB201519734D0 (en) | Cancer therapy | |
| GB201703907D0 (en) | Novel therapies for cancer | |
| GB201508480D0 (en) | Cancer | |
| HK1254687A1 (en) | Combination therapy for cancer | |
| HRP20210383T8 (en) | Combination therapy for cancer | |
| GB201511609D0 (en) | Cancer therapy | |
| GB201511120D0 (en) | Cancer therapy | |
| GB201511121D0 (en) | Cancer therapy | |
| GB201417819D0 (en) | Agents for cancer therapy | |
| GB201411884D0 (en) | Cancer therapy | |
| GB201409457D0 (en) | Molecules for cancer therapy | |
| GB201406529D0 (en) | Molecules for cancer therapy |